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Abstract  15 
Background: The performance of glucagon and GLP-1 immunoassays is often poor, but 16 
few sensitive LC-MS/MS methods exist as alternatives. Results: We established the first 17 
multiplexed LC-MS/MS method avoiding immunoenrichment for the quantitation of 18 
endogenous glucagon (LLOQ 15 pg/mL) and dosed GLP-1 (LLOQ 25 pg/mL) in human 19 
plasma. Specificity of endogenous glucagon quantitation was assured using a novel 20 
approach with a supercharging mobile phase additive to access a sensitive qualifier SRM. 21 
Endogenous glucagon concentrations were within the expected range, and showed good 22 
reproducibility after extended sample storage. A cross-validation against established 23 
immunoassays using physiological study samples demonstrated some similarities between 24 
methods. Conclusion: The LC-MS/MS method offers a viable alternative to immunoassays 25 
for quantitation of endogenous glucagon, dosed glucagon and/or dosed GLP-1. 26 
Keywords: glucagon, GLP-1, endogenous, plasma, LC-MS/MS, immunoassay, cross-27 
validation, supercharging mobile phase additive, m-NBA 28 
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Introduction  30 
Glucagon and glucagon-like peptide-1 (GLP-1) are peptide hormones encoded by the 31 
proglucagon gene, and are released from the gene product via tissue specific post 32 
translational processing (Figure 1).  33 
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 36 
Glucagon is released from pancreatic α cells and is a counter regulatory hormone that 37 
responds to hypoglycemia and fasting by stimulating glycogenolysis and gluconeogenesis, 38 
as well as hepatic fatty acid β-oxidation and ketogenesis [1]. It is also a biomarker for 39 
diseases such as diabetes  and neurendocrine tumours [2]. GLP-1 is released via secretion 40 
from intestinal L cells, and has primary roles in enhancing the β-cell insulin response to 41 
eating, enhancing β-cell survival, inhibiting gastric emptying, inhibiting glucagon secretion, 42 
and  suppressing appetite [1][3][4], as well as being of interest as a biomarker [5]. 43 
Pharmacological administrations of glucagon are known to increase energy expenditure [1], 44 
and therefore it is of interest along with GLP-1 for the development of obesity treatments 45 
[6][7].  46 
To study the physiological role of glucagon and GLP-1, and exploit their use as biomarkers, 47 
precise and accurate methods for determining their plasma concentrations are required. 48 
These are also needed to determine their pharmacokinetics in studies where these are 49 
dosed [6][7]. Traditionally such peptides are quantified using immunoassays. However 50 
precision and accuracy can be poor, as can be the correlation between assays 51 
[8][9][10][11][12][13]. This is often attributed to the potential for antibodies to cross-react with 52 
similar compounds, including inactive degradation fragments and metabolites. Specificity is 53 
particularly challenging for GLP-1 assays due to the large number of isoforms present that 54 
may cross-react. GLP-1 1-37, 7-37, and 9-37 are produced from differential cleavage of the 55 
pro-glucagon precursor [11]. In humans these primarily exist in C-terminal amidated isoforms 56 
(GLP 1-36NH2, 7-36NH2, and 9-36NH2) [4] [11][14]. GLP-1 7-36NH2 is the biologically active 57 
form and is referred to by the unqualified GLP-1 nomenclature. Similarly, some glucagon 58 
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immunoassays assays are known to cross-react with proglucagon products glicentin and 59 
oyntomodulin [9]. Glucagon metabolites, some of which have only been recently reported 60 
[15], may also cross-react. 61 
These concerns cast doubt on the integrity of some of the data in the literature. Cross-62 
validations to help assess the performance of different kits and laboratories can be 63 
impractical, as kits can be expensive, resources may not be available for training, and assay 64 
specific equipment may be required. For example only one of seven glucagon 65 
immunoassays recently evaluated used a standard microplate reader [9]. In addition 66 
radioimmunoassays (RIA) necessitate additional health and safety precautions during set-up 67 
and require specialised disposal of radioisotopes. 68 
LC-MS/MS based methodologies can help to overcome some of these challenges. For 69 
example, specificity can be improved by monitoring SRM transitions that incorporate the full 70 
length peptide and a related fragment ion, which will exclude many structurally similar 71 
compounds, and extraction methodologies and chromatographic separations can be tailored 72 
to the peptides of interest. Furthermore qualifier SRM transitions can be monitored, provided 73 
sufficiently sensitive transitions can be determined, to ensure results are consistent with 74 
those achieved from the quantitation SRM [16][17][18][19]. Inter-lab cross validations are 75 
also easier as methods can be transferred between LC-MS/MS systems with limited re-76 
optimisation.  77 
However the application of LC-MS/MS for glucagon and GLP-1 quantitation has been 78 
limited, primarily due to sensitivity challenges. Typical human plasma glucagon 79 
concentrations are in the region of 30 pg/mL, which can increase by 30 - 100 pg/mL as a 80 
result of hypoglycemia, but decrease to 3 – 7 pg/mL during hyperglycaemia [9]. GLP-1 is 81 
typically present at lower plasma concentrations, at approx. 13 pg/mL for fed  and 2 pg/mL 82 
for fasted subjects [20]. 83 
Despite these challenges, some sensitive LC-MS/MS methods have been reported. We 84 
described a method capable of routinely quantifying glucagon to 25 pg/mL using 400 µL 85 
plasma [21]. Another group recently described a multiplexed LC-MS/MS method capable of 86 
quantifying endogenous glucagon to 2.7 pg/mL and GLP-1 to 2.6 pg/mL using 500 µL 87 
plasma [20], which was a refinement of their previous method using 1000 µL [22]. However 88 
these methods used immunoaffinity enrichment with magnetic beads coated with anti-89 
analyte antibodies, adding expense and complexity to the method, and the methods had 90 
long LC run times (ca 15 minutes) due to the use of microflow LC to obtain the required 91 
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sensitivity. Methods for GLP-1 quantitation avoiding immunochemistry have much higher 92 
LLOQs, for example 66 pg/mL in a recent paper [23]. 93 
In this study we refined and expanded our previous method, to improve sensitivity, 94 
robustness and throughput, and to add GLP-1 as a secondary analyte. The method was 95 
qualified using fit-for-purpose criteria based on key experiments from FDA [24] and EMA [25] 96 
bioanalytical validation guidelines. We also describe the novel use of a supercharging mobile 97 
phase additive, meta nitrobenzyl alcohol (m-NBA), to obtain a sensitive qualifier SRM 98 
transition to ensure specificity of endogenous glucagon quantitation. The method was cross-99 
validated against two established immunoassays for each analyte using the same 100 
physiological study sample set. 101 
  102 
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Experimental 103 
Chemicals and Materials 104 
Certified human glucagon (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) was obtained from 105 
EDQM (Strasbourg, France). The analogue internal standard (IS) (des-thr7-glucagon) 106 
(HSQGTFSDYSKYLDSRRAQDFVQWLMNT) and stable isotope labelled (SIL) internal 107 
standard (HSQGT-[13C9;
15N]F-TSDYSKYLDSRRAQDFVQW-[13C6;
15N]L-MNT) were obtained 108 
from Bachem (Bubendorf, Switzerland). GLP-1 (7-36) amide 109 
(HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR - NH2) was also obtained from Bachem.  110 
Water was produced by a Triple Red water purifier (Buckinghamshire, U.K.). All chemicals 111 
and solvents were HPLC or analytical reagent grade and purchased from either Fischer 112 
Scientific (Loughborough, UK) or Sigma Aldrich (St Louis, MO USA). 113 
Preparation of Stock and Spiking Solutions 114 
Stock solutions of glucagon and glucagon internal standards (1 mg/mL), and stocks of  115 
GLP-1 (0.1 mg/mL), were prepared in borosilicate glass vials using surrogate matrix [MeOH: 116 
H2O: Formic acid (FA): Bovine serum albumin (BSA), (20/80/0.1/0.1, v/v/v/w); typically 117 
200mL H2O, 800mL MeOH ,1mL FA and 1 g BSA]. Combined glucagon and GLP-1 working 118 
solutions were prepared by dilution with this solvent to create nine calibration standard 119 
spiking solutions (300, 500, 900, 2000, 6000, 12000, 20000, 37000 40000 pg/mL), and six 120 
quality control spiking solutions (300, 500, 900, 1500, 4000, 35000 pg/mL). A mixed internal 121 
standard working solution (ISWS) containing both analog glucagon and SIL glucagon was 122 
similarly prepared at 20 ng/mL. The stock and working solutions were prepared to a volume 123 
of 10 mL and were stored at -20 C when not in use, as we previously  demonstrated  that 124 
glucagon solutions were stable under these conditions [21].  125 
Method Development  126 
The previously reported method [21] was refined to increase sensitivity, robustness and 127 
throughput. Various changes to the extraction procedure and LC conditions were 128 
investigated, as summarised in Supplementary information Table 1. SRM transitions 129 
corresponding to the SIL glucagon IS and GLP-1 were identified and optimised. Mobile 130 
phases were modified with various proportions of the supercharging additive m-NBA (meta  131 
nitrobenzyl alcohol) and formic acid to attempt to improve sensitivity. Further information is 132 
presented in Supplementary Information Sections 1-5. The resulting extraction and LC-133 
MS/MS methods used for the qualification are detailed below.  134 
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Quantitation Strategy 135 
A surrogate matrix based approach was used for glucagon quantitation. Plasma QCs, to 136 
represent samples, were created by diluting spiking solutions 20-fold into EDTA plasma to 137 
200 (MED) and 1750 (HIGH) pg/mL, and the QC concentration adjusted for the endogenous 138 
concentration. These were extracted and analysed according to the qualified extraction and 139 
LC-MS/MS methods described below. Calibration standards, QC LLOQs (precision and 140 
accuracy batches only) and QC LOWs were then prepared by spiking 20 µL of the 141 
appropriate spiking solution into the collection plate, along with 20 µL of ISWS and 160 µL 142 
surrogate matrix. Taking into account the 2-fold concentration experienced by plasma 143 
samples (400 µL of plasma sample is reconstituted into 200 µL of solvent) this gave final 144 
calibration levels of 15, 25, 45, 100, 300, 600, 1000, 1850, and 2000 pg/mL, and final QC 145 
levels of 15 (QC LLOQ) and 45 (QC LOW) pg/mL. 146 
Endogenous GLP-1 could not be detected, and therefore GLP-1 quantitation was performed 147 
as per an exogenous compound with calibrants and QCs prepared in the sample matrix 148 
(EDTA Plasma). Spiking solutions were diluted 20-fold into plasma to produce calibrants at 149 
25, 45, 100, 300, 600, 1000, 1850 and 2000 pg/mL and QC concentrations at 25 (LLOQ), 75 150 
(LOW), 200 (MED), and 1750 (HIGH) pg/mL. These were extracted according to the 151 
qualified extraction method. 152 
Qualified Extraction Method  153 
Plasma sample (EDTA) (400 µL) was placed into a 2mL 96 well plate and 20 µL of ISWS 154 
was added to all non-blank samples. This step was performed on ice to ensure analyte 155 
stability [26]. The plate was vortex mixed, and samples precipitated using 1.1 mL of 156 
ACN:H2O:NH3 (72:25:0.1,v/v/v), vortex mixed, sonicated for 5 minutes, and then centrifuged 157 
for 10 minutes at 2300 x g. 1.2mL of supernatant was transferred using an automated liquid 158 
handling system (Quadra Tower, TomTec, Connecticut, USA) to a 2 mL plate and 159 
evaporated to dryness at 40C under nitrogen (ca 90 minutes). Samples were reconstituted 160 
in 800 µL 2% NH3 (aq) and then vortex mixed, before being extracted using solid phase 161 
extraction (SPE) as per our previously reported method [21] A Bond Elut Plexa 96 round-well 162 
SPE plate (30 mg) was conditioned using 1 mL MeOH, then equilibrated with 1 mL H2O. The 163 
samples were loaded, washed with 1 mL 5% MeOH (aq), eluted with 2 x 225 µL 164 
ACN:H2O:FA (75:25:0.1, v/v/v) into a 1 mL Lo-bind plate, and then evaporated under 165 
nitrogen at 40C, before being reconstituted in 200 µL 0.2% FA (aq). The plate was 166 
centrifuged for 10 minutes at 2300 x g, and 40 µL of sample injected on to the LC-MS/MS 167 
system for analysis, or the plate stored at 4C awaiting injection. The entire process took 1 168 
working day. 169 
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Qualified LC-MS/MS method (formic acid phases)  170 
The LC-MS/MS system consisted of a Waters Acquity UPLC system (Waters Corporation, 171 
Massachusetts, USA) coupled to an AB SCIEX 5500 (Applied Biosystems / MDS SCIEX, 172 
Ontario, Canada) with an electrospray ion source.  173 
Glucagon was separated on a Waters Acquity UPLC BEH C18 1.7 µm (2.1 x 100 mm) 174 
column maintained at 60 C. The mobile phase consisted of (A) 0.2% FA in acetonitrile 175 
(ACN) and (B) 0.2% FA (aq). The gradient for glucagon elution was 22 - 32% A over 2 176 
minutes, as in our previous method [21], followed by a gradient of 32 - 38% over 0.8 minutes 177 
for GLP-1 elution. The column was then cleaned with 95% A for 0.75 minutes then re-178 
equilibrated at the starting conditions for 0.05 minutes. The flow rate was 0.8 mL/min and the 179 
total gradient time was 3.6 minutes per sample. 180 
The mass spectrometer was operated in positive ion mode with an electrospray voltage of 181 
5500 V. The source temperature was 600C, the curtain, N2 collision, GS1, and GS2 gases 182 
were set to 40, 8, 60, 40 psi respectively. The Q1 and Q3 quadrupoles were both operated 183 
at unit resolution. Entrance potentials of 10 V and collision exit cell potentials of 13 V were 184 
used. MS periods were used to maximise dwell times, and therefore sensitivity. The selected 185 
reaction monitoring (SRM) transitions 697.5694.0, 677.4673.8 and 702.2698.8 for 186 
glucagon, analogue glucagon IS, and SIL glucagon IS were monitored between 0 – 2 187 
minutes. These transitions were attributed to [M+5H+]5+  [M+5H+-NH3]
5+ in each case.   188 
Transitions used the optimal CE of 20, 18, and 20 respectively and all used dwell times of 60 189 
ms with declustering potential (DP) of 80. The SRM transitions 660.6656.9 and 190 
660.6752.0, which were attributed to [M+5H+]5+  [M+5H+-NH3]
5+  and [M+5H+]5+  y20
3+ 191 
respectively, were monitored for GLP-1 between 2 - 3.6 minutes. These transitions used the 192 
optimal CE of 16 and 22, and DP of 100 and 110 respectively and all used dwell times of 193 
100 ms. 194 
Qualified LC-MS/MS Method (m-NBA mobile phases)  195 
The same LC-MS/MS systems were used as above. However the mobile phase consisted of 196 
(A) 0.01% (FA) in ACN with 0.05% m-NBA and (B) 0.01% FA (95/5 H2O/ACN) with 0.05% 197 
m-NBA. The addition of ACN to the aqueous phase enabled solubility of the m-NBA. The 198 
gradient for glucagon elution was 18–28% A over 2 minutes, then 28 -34% over for 0.8 199 
minutes for GLP-1 elution, before being cleaned and re-equilibrated as above. MS settings 200 
were as above, unless stated differently below. The selected reaction monitoring (SRM) 201 
transitions 581.5578.5, 564.7561.8 and 585.5582.4 for glucagon, analogue glucagon 202 
IS and SIL glucagon IS were monitored between 0 – 1.75 minutes. These transitions were 203 
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attributed to [M+6H+]6+  [M+6H+-NH3]
6+ in each case. Transitions used the optimal CE of 204 
13, 12, 13 respectively and all used DP of 80 and dwell times of 60 ms. The SRM transitions 205 
550.6601.6 and 550.6639.3 were monitored for GLP-1 between 1.75 - 3.6 minutes. 206 
These transitions were attributed to [M+6H+]6+ y16
3+ and [M+6H+]6+ y17
3+ respectively. 207 
Transitions used the optimal DP of 80 and 70 respectively and both used CE of 19 and dwell 208 
times of 100 ms. 209 
Qualification Procedure  210 
The qualification experiments were based on key experiments described in the  FDA [24] 211 
and EMA [25] bioanalytical guidelines. Analyst v 1.6.2 (Applied Biosystems / MDS SCIEX, 212 
Ontario, Canada) was used to process data and to construct calibration lines. Duplicate 213 
calibration standards were analysed within each batch, and calibration lines were 214 
constructed using peak area ratio-concentration plots withlinear regression and 1/x2 215 
weighting. 216 
For glucagon our acceptance criteria required that the accuracy of ≥75% of standards in 217 
each batch was within 15% (20% at the LLOQ) of the nominal concentration, with those 218 
outside this excluded from the calibration line.. For precision and accuracy batches QCs 219 
needed mean accuracy within 20%, with precision (CV) 20% at each level. In other batches 220 
≥2/3 of the individual QCs needed accuracy within 20%, with at least one QC at each level. 221 
For GLP-1 similar acceptance criteria was used, expect that a 25% criteria was used for 222 
precision and accuracy at all levels. 223 
Precision and accuracy of the method was assessed by analysis of replicate (n=6) QC 224 
samples at at least four different concentrations within a batch. Selectivity was determined 225 
by inspecting chromatograms from six independent plasma EDTA samples for the presence 226 
of potentially interfering peaks.  227 
The effect of the presence of matrix to the response of the  analyte and internal standard 228 
was determined from six independent plasma EDTA samples. These were extracted and 229 
post spiked at the 200 pg/mL level, and compared to the mean response from samples in 230 
surrogate matrix taking into account endogenous concentrations. In addition QCs were 231 
fortified at 200 pg/mL in six independent Plasma EDTA matrices (1 aliquot of each), and in 232 
lithium heparin plasma (n=6).  233 
 234 
Stability in matrix was determined by spiking a plasma sample at 200 pg/mL and incubating 235 
it at room temperature or ice for 4 hr 50 minutes before extraction (n=6 replicates), and 236 
compared to a sample immediately extracted. The ability to re-inject extracts was assessed 237 
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at the P&A QC levels after 42 days storage at 4C. Analyte recovery was evaluated by 238 
comparing samples (n=6) spiked with 200 pg/mL analyte, with extracts post spiked at this 239 
level to represent 100% recovery. The 10-fold dilution of a QC HIGH sample (1750 240 
pg/mL)(n=6) with EDTA plasma was used to demonstrate whether low samples volumes 241 
could be analysed. 242 
Collection of samples from volunteers to assess endogenous glucagon concentrations  243 
Blood was collected from 11 male and 11 female healthy volunteers using glass plasma 244 
collection tubes (5 mL, EDTA anticoagulant) , obtained from BD (Oxford, UK). Tubes were 245 
placed on ice immediately after sample collection and then centrifuged at 2300 x g for 10 246 
minutes to obtain plasma, which was stored at -80C. Plasma was collected at the start of 247 
the working day and volunteers were not asked to change their usual eating regime.  248 
Glucagon concentrations were determined using the qualified method with formic acid 249 
phases. Concentrations were determined upon the first freeze-thaw of the aliquot, as 250 
multiple cycles have been shown to affect quantitation [21]. The ability to extrapolate below 251 
the 15 pg/mL for glucagon limit of quantitation was assessed by determining precision and 252 
accuracy of surrogate matrix QCs (n=6) diluted to 10 and 7.5 pg/mL levels. 253 
Samples containing endogenous levels of glucagon above the lower limit of quantitation (15 254 
pg/mL) were reanalysed after storage for up to 249 days at -80C to assess incurred sample 255 
reproducibility (ISR).  Similarly a plasma pool from one male and one female individual was 256 
created from stored samples and analysed immediately after pooling and after additional 257 
storage for 42 days at -80C. 258 
Finally, extracts from a selection of samples (n=9), and corresponding calibration standards 259 
and QC samples were reanalysed with the qualified method using m-NBA mobile phases to 260 
access a sensitive qualifier SRM to assure the methods selectivity. 261 
Collection of physiological study samples 262 
A 20 mL blood sample was collected from ten fasting healthy volunteers (West London 263 
National Research Ethics Committee, ref. 11/LO/1782), one volunteer dosed with glucagon 264 
(15 pmol/kg/min iv) (London Central Ethics and Research Committee (13/LO/0925), and two 265 
volunteers dosed with GLP-1 (16 pmol/kg/min sc) (13/LO/1510). Immediately after collection, 266 
2 ml samples were decanted into various collection tube types: 1) K3 EDTA anticoagulant 267 
(ref 368860 – Becton Dickinson Vacutainer System, NJ, USA) with the addition of aprotinin 268 
(Bayer, Newbury, UK; final concentration 250 kallikrein inhibitor units/ml) and a DPPIV 269 
inhibitor (Ile-Pro-Ile, Sigma-Aldrich, Dorset, UK; final concentration 10 μg/ml); 2) K3 EDTA 270 
anticoagulant with the addition of aprotinin; 3) K3 EDTA anticoagulant with the addition of a 271 
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DPPIV inhibitor; 4) K3 EDTA anticoagulant alone; 5) lithium heparin (ref 367883 – Becton 272 
Dickinson Vacutainer System, NJ, USA) with the addition of aprotinin and a DPPIV inhibitor; 273 
6) lithium heparin with the addition of aprotinin; 7) lithium heparin with the addition of a 274 
DPPIV inhibitor and 8) lithium heparin alone. Following collection, tubes were placed on ice 275 
and centrifuged at 2300 x g for 10 minutes to obtain plasma, which was stored at -80C. Two 276 
further aliquots, collected in K3 EDTA tubes with aprotinin and DPPIV inhibitor, underwent 1 277 
and 2 further freeze/thaw cycles, respectively.  278 
Analysis of physiological study samples  279 
Samples of the same stabiliser type and anticoagulant from three of the ten fasting healthy 280 
volunteers were pooled together. One aliquot was reserved for endogenous level 281 
determination and a second aliquot was spiked with 200 pg/mL analyte.  Samples were 282 
analysed using the qualified LC-MS/MS method with formic acid mobile phases to assess 283 
the effect that a change of sample matrix had upon quantitation. 284 
 285 
The majority of the samples from five of the remaining seven fasting healthy volunteers 286 
(endogenous glucagon samples) were analysed by the LC-MS/MS method and by two 287 
immunoassays (50/50, 50/50 and 45/50 for the LC-MS/MS, first, and second immunoassay 288 
respectively).  The first immunoassay was a Homogenous Time Resolved Fluorescence 289 
(HTRF®) sandwich immunoassay (Cisbio, Codolet, France) (analytical sensitivity = 12.0 290 
pg/mL). The second was a Milliplex MAP (multi-analyte profiling) Human Metabolic Hormone 291 
Magnetic Bead Panel (Merck Millipore, Darmstadt, Germany) (minimum detectable 292 
concentration (MinDC) =13.0 pg/mL), which involved a sandwich immunoassay with 293 
fluorescence detection.  Samples from the other two fasting healthy volunteers were only 294 
analysed using one method format, and are therefore not considered further. The same 295 
formats were also used to analyse samples from the volunteer dosed with glucagon.  296 
Samples from the two volunteers dosed with GLP-1 were similarly analysed using the LC-297 
MS/MS method, and by either a Millipore active GLP-1 ELISA (Lowest standard = 6.6 298 
pg/mL) or the Milliplex MAP (MinDC = 1.2 pg/mL) described above. 299 
 300 
The various measures of immunoassay sensitivity quoted by the manufactures (i.e. 301 
analytical sensitivity/ MinDC/ lowest calibration point) were taken as equivalent to the lower 302 
limit of quantitation (LLOQ)  measurement of the LC-MS/MS method for the purpose of this 303 
study. For all immunoassays, intra-assay CVs were <10% across the working range. 304 
  305 
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Results and Discussion 306 
Method Development –Re-optimisation 307 
Initial development focused on re-optimisation of the glucagon method described previously 308 
[21] to attempt to improve sensitivity, robustness, and throughput for glucagon analysis. 309 
GLP-1 was the secondary analyte for the assay, and was not introduced at this stage. A 310 
summary of the re-optimisation is presented in Supplementary Information Table 1, and 311 
further details are given in Supplementary Information Sections 1-5. 312 
The protein precipitation solvent volume used to extract the 400 µL plasma samples was 313 
lowered from 3.2 mL to 1.1 mL. Such low plasma: solvent ratios were not previously 314 
investigated as they would usually lead to high matrix effects, however the subsequent use 315 
of SPE as part of the 2D extraction procedure minimised these. This alteration allowed the 316 
assay to be transferred from 5 mL tubes into 96 well plates, enabling the use of an 317 
automated liquid handling system to transfer the protein precipitation supernatant further 318 
reducing extraction time and increasing robustness. Additionally it reduced the supernatant 319 
evaporation time to ca 90 minutes, halving the extraction time to 1 working day, which is 320 
similar to the incubation period for some glucagon immunoassays [9]. 321 
Following SPE the reconstituted samples contained less insoluble material than observed 322 
previously [21], and upon analysis an interference peak (1.6 min) close to glucagon’s 323 
retention time (1.7) was eliminated (Supplementary Information Figure  2a vs b). This may 324 
be due to the lower transfer of solid protein precipitate using the automated system than with 325 
a manual transfer. The reduced matrix content associated with the modified method also 326 
eliminated the need for a lengthy column clean, shortening the LC gradient time to 3.6 327 
minutes and increasing analyte signal in the plasma extracts. 328 
A SIL glucagon IS was acquired to investigate whether this improved performance over the 329 
analogue IS used previously. Performance was similar under standard conditions, however 330 
the SIL IS gave better performance when matrix effects were high, and it was therefore 331 
selected to maximise robustness. The other parameters investigated did not result in an 332 
improvement of the method. 333 
  334 
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Method Development –Addition of GLP-1 335 
LC-MS analysis of GLP-1 showed that the [M+3H]3+, [M+4H] 4+ and [M+5H] 5+ charge states 336 
(m/z= 1009.5, 825.1, and 660.0) were observed using formic acid based mobile phases. The 337 
latter two being most intense, and of similar intensity to each other (Figure 2a). As with 338 
glucagon [21], very little fragmentation was observed at lower collision energies and once a 339 
critical energy was reached numerous low intensity products were observed. Following 340 
optimisation and evaluation of sensitivity and linearity, the 660.6656.9 and 660.6752.0 341 
SRM transitions were found to be similarly optimal, with sufficient sensitivity obtained at 342 
25 pg/mL for extracted plasma samples. Previously, either the 825.4  946.3 transition 343 
alone [20][22], or the 825.2946.4 transition summed with 825.2  643.2 [23] were found 344 
optimal. Differences in the LC-MS/MS systems used, including the use of nano or microflow 345 
LC in the previous studies, as well as variations in the nature of samples used for evaluation, 346 
may help to explain the discrepancies. 347 
Method Development –Supercharging Mobile Phase Additives  348 
One of the challenges for sensitive LC-MS/MS peptide bioanalysis is that signal is split over 349 
multiple charge states. Supercharging mobile phase additives, for example m-NBA, are 350 
known to alter the charge state distribution favouring higher charge states [27]. This is 351 
thought to be due to an increase in surface tension of the droplets in the electrospray 352 
source, decreasing the radius prior to columbic explosion, and consequently leading to 353 
charge concentration [28]. Sensitivity increases may result if the charge state distribution is 354 
reduced, or if the signal is increased due to improved analyte ionisability, as we have 355 
demonstrated for one large peptide in plasma extract [27]. However for glucagon whilst we 356 
previously demonstrated alterations in the charge state distribution (3, 4, 5+ to 4, 5, 6+) and 357 
an improvement in analyte signal in extracts, no overall increase in sensitivity  (signal to 358 
noise) resulted due to similar increases in background noise [27].  359 
 360 
It was decided to re-investigate the use of m-NBA to improve glucagon sensitivity with the 361 
re-optimised extraction method and to more fully investigate the effect of altering the m-NBA 362 
and FA content of the mobile phases. Furthermore it was planned to use the m-NBA method 363 
to provide a sensitive qualifier SRM to ensure assay specificity as described later, so an 364 
optimal method was required. The effect on GLP-1 was investigated, which similarly to 365 
glucagon demonstrated a shift in charge state distribution (Figure 2b). 366 
  367 
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 368 
 369 
Figure 2- GLP-1 Full Scan MS Spectra- a) Formic acid mobile phases (Mobile A= 0.2% FA (ACN) 370 
Mobile B= 0.2% FA (aq)), b) Supercharging (m-NBA) mobile phases (Mobile A= ACN: m-NBA:FA 371 
(100:0.1:0.1), Mobile B= H2O:ACN:FA:m-NBA (95:5:0.1:0.1) 372 
The charge state distribution and signal intensity of glucagon and GLP-1 were affected by 373 
changes in the m-NBA and FA composition of the mobile phases in both solution and 374 
plasma extracts (Supplementary Information 5.1 – 5.3). Initial results suggested that higher 375 
levels of m-NBA favoured higher charge states (Supplementary Information 5.1.1) with the 376 
5+ and 6+ charge state of glucagon being most dominant at 0.05% and 0.10% m-NBA 377 
respectively. However further experiments suggested that 0.05% m-NBA was optimal for 378 
both charge states (Supplementary Information 5.2). Significant changes in signal intensity 379 
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occurred with the alteration of mobile phase formic acid content, which did not occur when 380 
using standard mobile phases (Supplementary Information 5.1.2 vs 3.2). Interestingly mobile 381 
phases modified with low amounts of formic acid (e.g. 0.01%) gave optimal signal for both 382 
analytes, regardless of whether they were in solution or plasma matrix, although the 383 
absence of acid led to very low signal demonstrating its necessity for efficient ionisation. 384 
Overall mobile phases modified with 0.05%m-NBA 0.01% FA gave optimal signal in plasma 385 
and extract for both analytes. 386 
 387 
Plasma extracts were analysed using both the optimal m-NBA and standard formic acid 388 
mobile phase methods (Supplementary Information 5.3). Similar sensitivity (signal-to-noise) 389 
was obtained using both conditions for glucagon and GLP-1, suggesting that m-NBA the 390 
method could provide a sensitive qualifier SRM. Method performance using m-NBA modified 391 
phases were further characterised during the establishment.  392 
Quantitation Strategy 393 
The endogenous nature of glucagon presents additional challenges as an authentic matrix 394 
free of analyte cannot be acquired, and therefore approaches such as standard addition, 395 
surrogate matrix or surrogate analyte must be considered as described previously [21]. This 396 
assay used the surrogate matrix based approach for glucagon quantitation, where calibration 397 
standards are prepared in an analyte free surrogate matrix, allowing low levels of glucagon 398 
in plasma samples to be quantified without extrapolation. Ideally surrogate calibrants and 399 
surrogate QC samples would be extracted alongside plasma samples, but this was not 400 
possible due to non-specific binding of the analyte in surrogate matrix to the extraction 401 
materials. Therefore non-extracted surrogate samples were used, which were added to the 402 
plate after plasma samples had been extracted. 403 
Similarly, in such strategies it is common to evaluate the performance of plasma samples 404 
diluted with surrogate matrix to demonstrate parallelism between surrogate and authentic 405 
matrix [25][29][30]. However, this was not possible as dilution prevented the protein 406 
precipitation, which was required in the extraction procedure. Therefore the performance of 407 
QCs spiked with analyte on top of the endogenous levels against the surrogate calibration 408 
line was considered sufficient. 409 
Acceptable sensitivity for is usually demonstrated by assessing whether the analyte 410 
response at the LLOQ level is at least 5 times the average response due to background 411 
noise [25]. It is then assumed that an unknown sample at the LLOQ concentration would 412 
also have a similarly acceptable response. However, this will not necessarily be the case for 413 
surrogate matrix assays, due to differences in the recovery and matrix suppression between 414 
15 
 
the surrogate and authentic matrices. The previous method [21] had a mean analyte 415 
recovery of 51.2% and matrix suppression (matrix factor=0.746), and therefore the signal-to-416 
noise (S/N) required at the LLOQ was 13.1 to ensure that S/N for an authentic sample at the 417 
LLOQ level 5 (assuming an unchanged background level). However using the re-optimised 418 
extraction method the IS response from surrogate matrix and plasma samples were similar 419 
(Supplementary Information 5.4) demonstrating that recovery losses during plasma 420 
extraction were compensated by matrix enhancement. The increase in the signal-to-noise 421 
requirements of surrogate matrix LLOQs were therefore not required, and allowed 422 
establishment of a 15 pg/mL LLOQ with signal-to-noise 5. 423 
 424 
The assay was not sensitive enough to detect endogenous concentrations of GLP-1, 425 
therefore it was quantified using an exogenous quantitation strategy, where both calibrants 426 
and QCs were prepared in the authentic plasma matrix.  427 
Qualification  428 
The FDA [24] and EMA [25] bioanalytical validation guidelines do not formally consider large 429 
molecule or biomarker analysis by LC-MS/MS. However they are often used as the basis for 430 
such studies, as in this current work, as many experiments are applicable and alternative 431 
regulatory guidelines do not exist. When setting acceptance criteria for biomarker assays it is 432 
important to consider the natural variability of the biomarker, for glucagon plasma 433 
concentrations can vary widely (3 - 130 pg/mL), and therefore a very stringent acceptance 434 
criteria was not considered necessary. Considering this and the analytical challenges 435 
associated with the surrogate nature of the assay, a 20% value was used for glucagon 436 
precision and accuracy across all levels, which is often used for immunoassays. For GLP-1 437 
a 25% criteria at all levels was used for the interpretation of data from the dosed subjects 438 
because of the analytical challenges presented by the lack or a SIL or closely related 439 
analogue IS.  440 
Glucagon 441 
The performance of the developed method was initially assessed using formic acid based 442 
mobile phases. The assay was linear over the 15 - 1000 pg/mL calibration range assessed. 443 
Signal to noise was ≥5 at the LLOQ level (Figure 3a). Precision and accuracy (%RE and 444 
%CV) were within the 20% acceptance criteria across all levels assessed (Supplementary 445 
Information Table 5). 446 
Matrix enhancement was observed, however this was compensated by the enhancement of 447 
the SIL IS, so it did not affect quantitation (Supplementary Information Table 6). The assay 448 
16 
 
gave acceptable performance across 6 individuals matrices fortified with 200 pg/mL of 449 
glucagon, and also in lithium heparin plasma providing further evidence that the assay was 450 
not significantly affected a matrix changes (Supplementary Information Table 5). There were 451 
no interferences in the selectivity samples near glucagon’s retention time that could affect 452 
the quantitation. Recovery, determined at 200 pg/mL, was 50.7%. 453 
The performance of the method was similarly assessed using mobile phases modified with 454 
m-NBA, and comparable performance was observed (Supplementary Information Table 5 455 
and 6) demonstrating the methods suitability for providing a qualifier SRM to further assure 456 
selectivity as discussed later. 457 
Glucagon was unstable at room temperature (65.9%) but stable on ice (110.1%) when 458 
incubated for 4 hr 50 minutes, consistent with previous observations [31], which sufficiently 459 
encompassed processing times for all batches extracted. The ability to re-inject extracts was 460 
demonstrated after 42 days storage at 4C (Supplementary Information Table 11). Samples 461 
could be diluted 10-fold without affecting quantitation, enabling analysis in cases of low 462 
sample volume (Supplementary Information Table 5). 463 
  464 
 465 
Figure 3 Glucagon and GLP-1 LLOQ chromatograms. a )Glucagon surrogate matrix sample at 466 
15pg/mL (697.5/694.0) (S/N=7.6).  b) GLP-1 plasma sample at 25 pg/mL (660.6/752.0) (S/N= 5.6). 467 
a) Glucagon LLOQ  
b) GLP-1 LLOQ  
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GLP-1 468 
A SIL IS or a closely related analogue was not available for GLP-1. The glucagon internal 469 
standards were therefore selected to investigate whether they offered advantages over IS 470 
free quantitation for GLP-1. The GLP-1 assay was characterised for precision and accuracy 471 
using two different SRM transitions for each mobile phase to ensure the most appropriate 472 
was selected.  473 
Precision and accuracy (%RE and %CV) using formic acid phases was acceptable (25%) 474 
for all but one analyte SRM and internal standard combinations, with the 660.6/752.0 GLP-1 475 
SRM with the analogue glucagon internal standard giving the best overall sensitivity and 476 
performance (Supplementary Information Table 7). Signal to noise was ≥5 at the LLOQ level 477 
(Figure 3b). Performance was generally worse using m-NBA modified phases, especially at 478 
the LLOQ level. This is likely due to the glucagon internal standards performing differently 479 
under supercharging conditions to the GLP-1 analyte (Supplementary Information Table 7). 480 
Such phases were therefore not investigated further for GLP-1. 481 
GLP-1 matrix suppression was observed, whereas the analogue glucagon IS experienced 482 
matrix enhancement, however the ratio between the two was similar across the matrices 483 
(CV= 16%), so there was no effect on quantitation (Supplementary Information Table 8). In 484 
addition the assay gave acceptable performance across 6 individual matrices, and 6 485 
replicates of lithium plasma spiked with 200 pg/mL of analyte (Supplementary Information 486 
Table 7).  487 
There were no interferences in the selectivity samples at the GLP-1 retention time. As 488 
expected [31] GLP-1 was unstable at room temperature (9.6%) but stable on ice for 4 hr 50 489 
minutes (94.7%). The ability to re-inject extracts was demonstrated after 42 days storage at 490 
4C (Supplementary Information Table 11). GLP-1 recovery determined at 200 pg/mL 491 
(53.7%) was similar to glucagon’s, and it was demonstrated that samples could be diluted 492 
10-fold without affecting quantitation (Supplementary information Table 7). 493 
  494 
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Analysis of plasma from volunteers to determine endogenous glucagon concentrations  495 
Plasma was collected from 11 healthy males and 11 healthy females and glucagon levels 496 
determined using the qualified LC-MS/MS method with standard formic acid mobile phases. 497 
Plasma glucagon concentrations were between 15 pg/mL (BLQ) and 47.1 pg/mL (Table 1), 498 
similar to ranges reported in the literature  (3 to 130 pg/mL [9] or 27- 87 pg/mL [20]).  499 
Several samples contained evidence of glucagon, but the concentrations were BLQ 500 
(Figure 4). Numerical values were determined for indicative purposes by extrapolation of the 501 
calibration line, and are shown in parenthesis in Table 1. The performance of the method at 502 
the 10 pg/mL level, as determined by evaluation of surrogate matrix QCs, was reasonable 503 
(mean accuracy 87.4%, CV= 29.7%), however poor performance resulted at the 7.5 pg/mL 504 
level (Mean accuracy 68.6%, CV= 40.4%). This should be considered whilst evaluating 505 
concentrations below the established range. 506 
 507 
Figure 4 –Glucagon chromatograms from a a) BLQ (14.7 pg/mL) and b) within range (40.0 508 
ng/mL) sample 509 
Samples with glucagon concentrations levels above the LLOQ were reanalysed to assess 510 
incurred sample reproducibility (ISR) (Table 1). 6/9 (66.6%) of samples gave concentrations 511 
within 20% of the original concentration, therefore passing standard criteria. A further sample 512 
gave a BLQ value upon reanalysis, although as its original concentration was close to the  513 
15 pg/mL LLOQ, this was within the expected range. The storage time before reanalysis 514 
varied from 6 - 249 days, but no trend between the % difference and storage time was 515 
observed. 516 
Similarly, a pooled plasma sample (n=6 replicates) gave a re-assayed concentration (33.3 517 
pg/mL, CV=9.4%) within 4.3%  of its original concentration (31.9 pg/mL, CV=6.1%) following 518 
additional storage for 42 days at -80C (Supplementary information Table 9). This further 519 
demonstrated the method’s good reproducibility at the endogenous glucagon level.  520 
 521 
a) b) 
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Table 1 Incurred sample reproducability (ISR) assessment;  comparison of original and 522 
reassayed endogenous glucagon concentrations following storage. NS- No sample remaining 523 
for repeat analysis. % difference= 100* (reassayed concentration- original concentration)/original 524 
concentration. Pass= % difference within 20%, Fail= %difference outside 20%. 525 
Sample Days stored  
(-80C) 
 before   
original  
analysis  
Original 
Concentration 
(pg/mL) 
 
Days  stored 
at -80C 
 between  
analyses 
ISR 
 concentration  
(pg/mL) 
%  
difference 
Pass/ 
Fail 
M1  95 19.1 152 25.3 27.9 Fail 
M2 74 BLQ (8.50) 152 - - - 
M3  74 25.7 - NS - - 
M4  11 42.8 152 39.1 -9.0 Pass 
M5 11 34.1 249 44.8 27.2 Fail 
M6 11 27.2 249 27.8 2.2 Pass 
M7 15 BLQ (12.5) - - - - 
M8 36 BLQ (No Peak) - - - - 
M9  36 BLQ (No Peak) - - - - 
M10 38 BLQ (14.1) - - - - 
M11 38 45.9 6 50.4 9.3 Pass 
F1 95 BLQ (14.7) - - - - 
F2 95 40.0 152 41.9 -4.6 Pass 
F3 74 15.1 152 15.7 3.9 Pass 
F4 11 33.8 152 23.4 -36.4 Fail 
F5 11 BLQ (No Peak) - - N/A - 
F6 10 BLQ (10.3) - - - - 
F7 15 BLQ (9.46) - - N/A - 
F8 15 26.9 99 24.7 -8.5 Pass 
F9 36 BLQ (14.7) - - - - 
F10 38 BLQ (14.5) - - - - 
F11 38 15.5 6 BLQ (No Peak) - NA 
 526 
For exogenous compounds the absence of significant peaks at the analyte retention time 527 
can be used to demonstrate the selectivity of the method. This is not possible for 528 
endogenous compounds, and therefore additional SRM transitions can be monitored as 529 
qualifier transitions to ensure selectivity [16][17][18][19]. However for glucagon the only SRM 530 
sensitive enough to determine endogenous concentrations using formic acid mobile phases 531 
was that monitored (697.5/694.0). The method with mobile phases modified with m-NBA 532 
enabled access to an alternative sensitive qualifier SRM transition (581.5/578.5), derived 533 
from a higher charge state, as well as providing alternative LC conditions. Reanalysis of 534 
extracts using this method demonstrated concentrations were not significantly different to 535 
those originally obtained providing additional evidence for the selectivity of the formic acid 536 
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based mobile phase method (Table 2). As far as the authors knowledge the use of 537 
supercharging mobile phases for such an application has not been reported.  538 
Table 2 Determination of endogenous plasma gluagon concentrations using formic acid and 539 
m-NBA modified mobile phases and corresponding SRM transitions % difference= 100* 540 
(Qualification assay concentration – quantitative assay concentration)/quantitative assay 541 
concentration. BLQ. Below the limit of quantitation (BLQ). Extrapolated concentrations given in 542 
brackets. NC- not calculatable. 543 
Sample Glucagon Concentration (pg/mL) % Difference 
Quantitative  
assay 
Qualification 
assay  
0.2% FA Phases 
Glucagon  
(697.5/694.0) 
0.05%  m-NBA 
0.01% FA phases 
Glucagon  
(581.5/578.5) 
F1 BLQ (14.7) BLQ (12.6) -14.3 
F2 40.0 43.3 8.2 
F3 15.1 17.2 13.9 
F4 33.8 32.8 -3.0 
F5 No Peak No Peak NC 
M1 19.1 23.1 20.9 
M2 BLQ (8.50) No Peak NC 
M3 25.7 26.8 4.3 
M4 42.8 46.2 7.9 
 544 
  545 
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Cross validation against established immunoassays using physiological samples 546 
Plasma samples were available to cross-validate the LC-MS/MS method against established 547 
immunoassays.  These originated from a physiological study assessing the preanalytical 548 
stability of glucagon and GLP-1 in the presence of various stabilisers and anticoagulants. 549 
These did not introduce a significant matrix effect affecting LC-MS/MS quantitation 550 
(Supplementary Information Table 10). Samples originated from fasting healthy volunteers 551 
(endogenous glucagon), volunteers dosed with glucagon, and volunteers dosed with GLP-1.  552 
Results of the stability investigations at the endogenous glucagon level have been recently 553 
reported [32]. Two immunoassays using different assay formats were used to cross-validate 554 
each analyte against the LC-MS/MS method, to help provide confidence, or otherwise, of the 555 
immunoassays results. 556 
For endogenous glucagon quantitation, the HTRF immunoassay demonstrated limited utility 557 
as only 16/50 samples were above the LLOQ (12.0 pg/mL). In contrast, the majority of the 558 
samples analysed by the Millilpex assay (38/45) and LC-MS/MS method (39/50) gave 559 
quantifiable (≥LLOQ) concentrations.  Whilst this may be expected for the LC-MS/MS 560 
method, with its lower LLOQ (10.0 pg/mL), the Milliplex had a higher LLOQ (13.0 pg/mL). 561 
This discrepancy may be due to differences in the standardisation of reference materials 562 
between the immunoassays and/or the Milliplex being more susceptible to interferences. 563 
Only data above the LLOQ is discussed below, as large errors would likely be associated 564 
with lower concentrations, although for completeness all concentrations determined are 565 
shown in Supplementary Information Figure 11a. 566 
The endogenous glucagon concentrations measured by all three methods were within 567 
literature ranges (3 to 130 pg/mL [9] or 27- 87 pg/mL [20]) (Figure 5 and Supplementary 568 
Figure 11b). Where both the HTRF and LC-MS/MS methods gave quantifiable (≥LLOQ) 569 
concentrations, these were of similar magnitude with no notable inter-volunteer or 570 
anticoagulant effects (Figure 5a).  Likewise the LC-MS/MS and Milliplex methods gave 571 
similar concentrations for samples from volunteers 1, 2, and 5, and from the EDTA samples 572 
from volunteer 3 (Figure 5b). However the Milliplex gave significantly higher concentrations 573 
for lithium heparin samples obtained from volunteer 3, and for all samples from volunteer 4.  574 
The Millplex assay also showed a positive bias for samples from volunteer 4 in comparison 575 
to the HTRF when quantifiable (≥LLOQ) results were compared (Figure 5c). This suggests 576 
that the matrix from volunteer 4 affects Milliplex quantitation due to the presence of low level 577 
interferences sharing an epitope with glucagon or due to other non-specific interferences, as 578 
has been suggested previously [9]  Similarly, interferences may be present in lithium heparin 579 
samples from volunteer 3, affecting immunoassay quantitation. The poor sensitivity of the 580 
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HTRF, and potential susceptibility of the Milliplex assay to matrix interferes, demonstrates 581 
some of the challenges in selecting appropriate immunoassays for LC-MS/MS cross 582 
validation.  583 
 584 
 585 
 586 
Figure 5  Comparison of endogenous glucagon concentrations determined by  587 
LC-MS/MS and two immunoassays. a) HTRF vs LC-MS/MS. b) Milliplex vs. LC-588 
MS/MS, c) HTRF vs. Milliplex . Samples were analysed from 5 volunteers (1-5), 589 
which contained either EDTA (E) or Lithium Heparin (L) anticoagulant in addition to 590 
various stabilisers (not shown). Different stabiliser combinations were used in 591 
samples of the same Sample Type, e.g. the four 4E samples in Figure 5b are all 592 
unique. Only samples with quantifiable (≥LLOQ) results for both assays being 593 
compared are displayed. Full results are shown in Supplementary Information Figure 594 
11.  595 
 596 
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Concentrations of the samples from the volunteer dosed with glucagon strongly correlated 598 
between the two immunoassays, and similar absolute concentrations were determined 599 
(Figure 6a). This may be due to the absence of matrix interferences affecting the Milliplex 600 
assay from this volunteer, or interferences becoming negligible at higher glucagon 601 
concentrations. The LC-MS/MS method showed some similarity in concentrations trends 602 
between samples, although results were less comparable, and absolute concentrations were 603 
generally higher. This may reflect differences in the natures of the techniques; 604 
immunoassays detect specific epitopes whereas the LC-MS/MS method targets the whole 605 
molecule. It has been recently suggested that epitope masking caused by glucagon 606 
aggregation may artificially lower immunoassay assay concentrations in plasma samples 607 
fortified with high levels of glucagon [26]. A similar process may occur in samples from 608 
dosed patients also containing high levels of glucagon. In addition to generally higher LC-609 
MS/MS concentrations, this could also explain differences in concentration trends if 610 
aggregation occurred to various degrees in different samples. 611 
 612 
   613 
Figure 6  Comparison of concentrations determined by LC-MS/MS and two 614 
immunoassays in samples from volunteers dosed with a) glucagon and b)  615 
GLP-1. Samples were analysed from 1 volunteer (labelled 6) dosed with glucagon 616 
and 2 volunteers (labelled 7 & 8) dosed with GLP-1. Samples contained either EDTA 617 
(E) or Lithium Heparin (L) anticoagulant in addition to various stabilisers (not shown). 618 
Different stabiliser combinations were used in samples of the same Sample Type, e.g 619 
the six 6E samples are all unique. 620 
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Samples from the two volunteers dosed with GLP-1 showed similar concentrations trends 621 
between the samples across the three methods (Figure 6b).  Absolute concentrations 622 
showed a systematic bias of LC-MS/MS > Millpore> Milliplex. This could be due to 623 
differences in the standardisation of reference materials. Although it was also noted that 624 
lithium heparin samples from subject 7 showed similar immunoassay concentrations, 625 
suggesting a susceptibility of the assays to inter-volunteer and anticoagulant related matrix 626 
effects. The limited agreement of the immunoassays restricted their value to further cross-627 
validate the LC-MS/MS method. 628 
Overall, the cross-validation provided only limited confirmation for the performance of the  629 
LC-MS/MS method. However this was not unexpected as the poor performance of some 630 
immunoassays provided the main rationale for development of the LC-MS/MS method. 631 
Further investigations are needed with larger data sets, various sample types, and additional 632 
assays, to better characterise the performance of the developed LC-MS/MS method. 633 
  634 
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Conclusion 635 
We describe a multiplexed LC-MS/MS method for the quantitation of endogenous glucagon, 636 
dosed glucagon, and/or dosed GLP-1 in human plasma without immunoenrichment. The 637 
sensitivity achieved is the highest reported for both peptides for such an extraction. The 638 
methodology has been improved over the initial method through a significant shortening of 639 
extraction time, inclusion of a stable isotope labelled internal standard and a reduction in LC-640 
MS cycle time. The one day extraction compares well against many immunoassays, which 641 
often incur overnight incubation steps, as required by the Millipore and Millipex assays used 642 
in this study. Samples extracted for LC-MS/MS analysis can be run overnight to produce 643 
data is a similar overall time frame to immunoassays. Good precision and accuracy was 644 
obtained over the calibration range, and recovery, matrix effects, and bench top stability 645 
were acceptable. Endogenous glucagon specificity was assured by a novel approach using 646 
mobile phases modified with the m-NBA supercharging additive to access an alternative 647 
sensitive qualifier SRM transition. 648 
Endogenous glucagon concentrations were within the expected range, and determination 649 
was highly reproducible after extended sample storage (up to 249 days at -80C). A cross-650 
validation was performed using physiological samples with the qualified LC-MS/MS method 651 
and two immunoassays for each analyte. Some similarities between the LC-MS/MS method 652 
and immunoassays were observed for endogenous glucagon, but dosed glucagon and 653 
dosed GLP-1 samples showed a trend towards higher concentrations when measured by 654 
LC-MS/MS. It was however noted that immunoassays also showed some differences 655 
between each other, limiting their value for cross validation. Such differences were not 656 
wholly unexpected, as performance concerns associated with glucagon and GLP-1 657 
immunoassays provided the main rationale for development of the LC-MS/MS method. We 658 
therefore consider the LC-MS/MS method to be at viable alternative to immunoassay based 659 
approaches. 660 
However we appreciate that cost may be a limitation to the adoption of LC-MS/MS to routine 661 
clinical diagnostics in some laboratories. Whilst consumable costs are lower, with the largest 662 
being the SPE plate at a couple of hundred pounds (compared to several hundred pounds 663 
for immunoassays kits), LC-MS/MS instrumentation is considerably more expensive. 664 
Sensitive LC-MS/MS systems cost in the region of two hundred thousand pounds, whereas 665 
plate readers can be obtained for around 10 times less. Although as a platform technology 666 
LC-MS/MS enables rapid amortisation of the capital cost over multiple analytes. The uptake 667 
of LC-MS/MS within clinical laboratories is increasing, and therefore there is the potential to 668 
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initiate specialist centres with access to LC-MS/MS instrumentation, who could set up and 669 
run a glucagon LC-MS/MS service.  670 
Future Perspectives 671 
As instrumentation improves it will be possible to accurately quantity lower levels of 672 
endogenous glucagon as well as endogenous GLP-1 without the use of immunoenrichment. 673 
These will also allow sensitive qualifier SRM transitions to be obtained using standard formic 674 
acid mobile phases to ensure endogenous compound specificity, until then transitions may 675 
be accessed using mobile phase supercharging additives as described. The use of high 676 
throughput 2D extractions to minimise matrix suppression, may also become a more 677 
widespread strategy to improve sensitivity. Further development could also include the 678 
expansion of the assay to other proglucagon derived peptides, or other peptides of interest. 679 
Reproduction of LC-MS/MS methods at different laboratories will provide further confidence 680 
of the performance and robustness of these. 681 
The differences in glucagon and GLP-1 concentrations obtained using the various analytical 682 
methods is concerning, as they could lead to incorrect clinical decisions. Assays should be 683 
better characterised with regards to inter-subject and anticoagulant related matrix 684 
interferences, as well as for cross-reactivity with metabolites and degradation fragments. 685 
Characterisation may include the use of biological matrix reference materials containing 686 
independently certified amounts of analyte [33], but these are not currently available for 687 
glucagon or GLP-1. The ability of glucagon to aggregate in plasma, and its effect on 688 
quantitation, requires further study, and the standardisation of reference materials between 689 
assays should be improved. The benefit of using LC-MS/MS based methodologies is that 690 
specificity is enhanced over immunoassays, as they can target the full length molecule 691 
rather than specific epitopes, and therefore such methods may become increasingly utilised 692 
in the future. 693 
  694 
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Executive Summary 695 
 Background  696 
 Glucagon and GLP-1 are traditionally quantified in human plasma by immunoassay. 697 
However precision and accuracy can be poor, as can be the correlation between 698 
assays. 699 
 LC-MS/MS based approaches can be used as alternatives to help overcome such 700 
challenges; however their application has been limited by lower sensitivity. 701 
 This study refined and expanded our previous glucagon-only method, improving 702 
sensitivity, robustness, and throughput, and further demonstrated specificity of 703 
endogenous glucagon quantitation.  GLP-1 was also introduced as a secondary 704 
analyte. 705 
Experimental 706 
 Method refinements included modification of the 2D (protein precipitation then SPE) 707 
extraction protocol and the introduction of an automated liquid handling system to 708 
improve sensitivity, robustness, and throughout. 709 
 The multiplexed method was qualified based on key experiments described in the 710 
latest FDA and EMA bioanalytical guidelines. 711 
 A sensitive qualifier SRM was accessed via a novel application of a supercharging 712 
mobile phase additive to ensure specificity of endogenous glucagon quantitation.  713 
 Physiological study samples were quantified using the qualified LC-MS/MS assay, 714 
and a cross-validation was performed against established immunoassays.  715 
  716 
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Results and Discussion 717 
 Method refinements halved the extraction time to 1 working day (96 samples) and 718 
UHPLC run time to 3.6 minutes/samples, significantly improving throughput. 719 
Sensitivity was improved by reduced matrix suppression in the refined method. 720 
 The method was successfully multiplexed with GLP-1, and met the qualification 721 
criteria for both analytes. 722 
 Endogenous glucagon concentrations were determined within the expected range, 723 
and confirmed by comparison to a sensitive qualifier SRM. Concentrations showed 724 
good reproducibility after extended sample storage. 725 
 Glucagon and GLP-1 concentrations were determined from physiological study 726 
samples containing endogenous glucagon, dosed glucagon and dosed GLP-1. 727 
 Cross-validation against immunoassays using the physiological study samples 728 
showed some similarities between the methods. However differences were not 729 
wholly unexpected, as performance concerns associated with glucagon and GLP-1 730 
immunoassays provided the main rationale for development of the LC-MS/MS 731 
method. 732 
Conclusion 733 
 The sensitivity achieved (Glucagon- 15 pg/mL LLOQ, GLP-1- 25 pg/mL LLOQ) is the 734 
highest reported for both peptides for an extraction avoiding immunoenrichment  735 
 The method provides a viable alternative to immunoassay based approaches for the 736 
quantitation of endogenous glucagon, dosed glucagon, and/or dosed GLP-1 from 737 
human plasma samples. 738 
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Table S1  Parameters re-optimised during assay development for glucagon quantitation  5 
Parameter Re-optimised Aim Result 
Method 
altered? 
Sup 
Info 
Ref 
Protein 
Precipitation 
Solvent  
 
Composition  
Increase sensitivity by increasing recovery and/or 
reducing matrix effects 
Original solvent (75/25/0.1, ACN/H2O/NH3) gave 
optimal performance  
No 1.1 
Volume 
Reduce extraction time by reducing solvent volume to 
enable use of 96 well plates and associated 
automated liquid handling, as well as reducing 
evaporation time.  
Volume reduced from 3.2 mL to 1.1 mL. 
Automated liquid handling utilised. Extraction time 
halved to 1 day.  
Yes 1.2 
Evaporation 
temperature 
Reduce evaporation time 
Higher temperatures (60C) led to increased 
matrix interference. 
No 1.3 
Extract Reconstitution Volume 
Increase sensitivity by reducing reconstitution volume 
to increase extract concentration  
Reduced volume increases background noise, 
lowering signal-to-noise.  
No 2 
LC 
Flow Rate 
Increase sensitivity, as a result of higher ionisation 
efficiencies at lower flow rates. Monitor multiple charge 
states to ensure optimal is selected.  
No overall boost in sensitivity was observed due 
to increased peak broadening at lower flow rates. 
Original charge state was optimal. 
No 3.1 
Formic acid 
composition 
Increase sensitivity, by increasing positive electrospray 
ionisation at lower pH  
Sensitivity reduces at lower pH.  No 3.2 
Column clean 
time 
Reduce run time by reducing column clean, enabled 
by lower matrix build up by automated liquid handling. 
Column clean time reduced by 3 minutes, leading 
to a gradient time of 3.6 min per sample, saving 5 
hours of analysis time per 96 sample batch.   
Yes 3.3 
Internal Standard 
Increase precision  and accuracy, and robustness 
using SIL rather than an analogue glucagon IS  
SIL IS gave better performance under conditions 
of high matrix effect.   
Yes 2 & 4 
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1 Extraction Optimisation 6 
1.1 Protein Precipitation Solvent Composition 7 
Previously we investigated ACN based protein precipitation solvents diluted to various 8 
proportions (0, 25, 50%) with water  [1]. We found that 75/25 ACN/H2O gave the best 9 
response, and that the addition of 0.1% formic acid significantly reduced it, whilst the 10 
addition 0.1% ammonia gave a small increase. Therefore 75/25/0.1 ACN/H2O/NH3 was 11 
selected. To attempt to increase performance further in this sutdy we investigated additional 12 
proportions of ACN in water (20, 15, 10, 5%) and investigated the use of MeOH based 13 
solvents, however the original solvent remained optimal (Figure S1). We have found in our 14 
laboratory that using 25% water in acetonitrile is often the optimal protein precipitation 15 
solvent for peptide analysis. 16 
 17 
Figure S1  Effect on analyte and analogue internal standard (IS) peak areas upon 18 
extracting plasma samples (100 µL) spiked with 1 ng/mL glucagon with various protein 19 
precipitation solvents  20 
  21 
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1.2 Protein Precipitation Solvent Volume 22 
The protein precipitation solvent volume was reduced (3.2 mL to 1.1 mL) to enable the assay 23 
to be performed in a 2mL 96 well plate, rather than tubes. Interference peaks (1.6 min) close 24 
to glucagon’s retention time (1.7 min) were eliminated (Figure S2 a vs b). 25 
 26 
 27 
 28 
Figure S2 Effect of the extraction method on interference peaks.  The matrix interference 29 
(1.6 min) close to the analyte retention time observed using the a) original extraction procedure is 30 
removed using the b) modified extraction procedure. c) Increasing the solvent evaporation 31 
temperature to 60C resulted in a slight decrease in internal standard response and an increase in 32 
tailing. 33 
  34 
a) 
b) 
c) 
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1.3 Protein Precipitation Solvent Evaporation Temperature 35 
The blow down temperature was increased from 40C to 60C to attempt to reduce 36 
evaporation time. No significant difference in analyte signal (Figure S2 b vs c) or QC 37 
accuracies were observed, however the IS showed slightly lower signal and greater tailing. 38 
As the difference in evaporation time was small (75 min vs 95 min), it was decided to 39 
maintain the temperature at 40C. 40 
2 Extract Reconstitution Volume  41 
Lower extract reconstitution volumes were investigated to attempt to boost sensitivity. 42 
However whilst signal did increase the background noise increased to a greater extent, 43 
leading to a reduction in signal-to-noise with a constant 40 µL injection volume (18.4, 15.5, 44 
12.9, at 200, 150, 100 µL reconstitution volumes respectively for a 100 pg/mL sample).  45 
The Analye/internal standard peak-area-ratio (PAR) was also affected at low reconstitution 46 
volumes (100 µL) using the analogue internal standard for 100 and 750 pg/mL samples, 47 
affecting quantitative accuracy and demonstrating the limitation of the analogue internal 48 
standard under conditions of high matrix effects (Table 2).  49 
Table 2  Effect of reconstitution volume on extracted plasma QC performance, 50 
quantified using the analogue and SIL glucagon internal standard. 51 
Reconstitution 
volume (µL) 
Glucagon Internal Standard 
Analogue SIL 
100 pg/mL 750 pg/mL 100 pg/mL 750 pg/mL 
% 200 µL  
PAR 
%CV % 200 µL  
PAR 
%CV % 200 µL  
PAR 
%CV % 200 µL  
PAR 
%CV 
200 100.0 2.0 100.0 5.7 100.0 1.6 100.0 4.1 
150 97.7 1.7 99.8 0.2 103.7 1.6 102.8 1.1 
100 78.1 3.6 89.8 6.9 98.5 1.3 104.3 2.6 
3 LC Optimisation 52 
3.1 Flow Rate 53 
Lower LC-flow rates (0.25 mL/min and 0.40 mL/min) were investigated to see whether they 54 
increased sensitivity over the original (0.80 mL/min) flow rate, due to improved ionisation 55 
efficiency.  To reduce the effect of peak broadening flow rates were lowered only during 56 
analyte elution.  57 
Lower flow rates were noted to increase the relative formation of the highly charged 4+ ion 58 
(m/z = 697), as expected due to prolonged interaction with the electrospray probe allowing 59 
greater charge accumulation. Peak areas increased with lower flow rates (Figure S3b), 60 
however peak broadening was still significant, and therefore there was no overall significant 61 
increase in peak height (sensitivity) (Figure S3b).  The flow rate was maintained at 0.8 62 
mL/min. 63 
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 64 
Figure S3  Effect of the flow rate on (a) peak area and (b) heights for various glucagon 65 
charge states using 1ng/mL solution.  Flow rate is 0.8 mL/min except at elution. Mobile phases A= 66 
0.2% FA (ACN) B= 0.2% FA (aq).  67 
3.2 Formic Acid Composition  68 
The percentage of formic acid in the mobile phases was investigated using 1 ng/mL 69 
glucagon solutions (Figure S4). Reducing formic acid from 1% to 0.2% increased the 70 
intensity of all charge states, including the most highly charged 5+ (m/z= 697) charge state, 71 
without significantly affecting the charge state distribution. Higher percentages of formic acid 72 
may increase ionisation of matrix components, limiting ion current available for analyte ions. 73 
However the proportion of the 5+ (m/z = 697) charge state reduced in abundance when 74 
formic acid was lowered further to 0.1%, as the lower 4+ (m/z= 871) charge state was 75 
favoured. Peaks height and peak area were similarly affected, as there was not effect on 76 
peak broadening. 0.2% FA remains optimal for the 5+ (m/z = 697) charge state. 77 
 78 
Figure S4  Effect of the formic acid content on glucagon (a) peak area and (b) height.  79 
Flow rate is 0.8 mL/mL, mobile phases are A=ACN and B=water, each modified with formic acid 80 
to the extent shown in the figure. 81 
3.3 Column clean time 82 
The original LC method included a 4 minute column clean step at the end of each injection at 83 
the LC starting conditions (22% organic). This was found necessary to reduce column 84 
fouling, and resulted in a run time of 7.1 minutes. To attempt to reduce run time this was 85 
reduced to 0.4 minutes, which as expected led to column fouling during the injection of 86 
samples extracted using the original extraction method (Figure S5a vs b), however peak 87 
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shape was maintained using the re-optimised extraction method with automated liquid 88 
transfer (Figure S5c vs d). This was attributed to the reduction of the inadvertent transfer of 89 
protein precipitate solid, and subsequent reduction of matrix build up on the column. The 90 
total run time for the final multiplexed method was 3.6 minutes, saving 5 hours of analysis 91 
time per 96 sample batch. 92 
  93 
  94 
Figure S5  Comparison of SIL internal standard peak shape  using the original extraction 95 
procedure at plasma injection a) 9 and b) 33, and using the re-optimised extraction procedure 96 
at plasma injection a) 9 and b) 33. 97 
 98 
4 Internal Standard 99 
Table 3  Performance of the analogue and SIL glucagon internal standard against 100 
plasma QC samples extracted using the original [1] or re-optimised extraction procedure with 101 
plasma samples 102 
Plasma QC  
Concentration 
(pg/mL) 
Extraction  
Method 
Glucagon Internal Standard 
Anologue SIL 
% Accuracy %CV % Accuracy %CV 
MED 
100 pg/mL 
Original  114.0 6.2 97.8 4.3 
Re-optimised 98.5 5.5 92.0 5.5 
HIGH 
750 pg/mL 
Original  114.8 2.9 97.6 3.6 
Re-optimised 102.9 3.5 100.4 4.5 
  103 
a) b) 
c) d) 
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5 Mobile Phase Supercharging Reagents 104 
5.1 Initial Optimisation  105 
5.1.1 Optimisation of m-NBA content in mobile phases  106 
The percentage of m-NBA in the mobile phases was found to have a large effect on the 107 
charge state distribution of glucagon (Figure S6). As expected higher percentages favoured 108 
the most highly charged species (6+, m/z =581). At low levels of m-NBA (0 - 0.50%) the 109 
response of both the (6+, m/z =581) and 6+(m/z= 697) ions increased with m-NBA 110 
concentration, presumably due to an increase in overall ionisation efficiency. Whereas at 111 
higher levels of m-NBA the increase of the 6+ (m/z =581) charge state was at the expense of 112 
the others. Data points were only collected for the 3+ and 4+ ions at 0 and 0.1% m-NBA 113 
concentrations, as these ions were least intense and therefore discarded early on in method 114 
development.  115 
 116 
Figure S6  The effect of m-NBA mobile phase content on charge state distribution. Mobile 117 
phases are A= ACN, B= H2O/ACN (95/5), both modified with m-NBA as shown. A 1000 pg/mL 118 
surrogate standard (n=3 replicates) was analysed in each case. These data are from 3 different 119 
experiments (Exp1 (full scan):  0 & 0.1% m-NBA, Exp2 (SRM): 0.025 & 0.050% m-NBA, Exp 3 120 
(SRM):0.05 & 0.1% m-NBA). SRM transitions were 697/693 and 581/575. Data has been scaled 121 
appropriately, using common conditions between experiments, to account for signal variations. 122 
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5.1.2 Optimisation of Formic acid content in mobile phases 124 
The effect of adjusting the percentage of formic acid in mobile phases was relatively small in 125 
standard mobile phases (Section 3.2), however when m-NBA was present the effect was 126 
significant (Figure S7). Acids are known to decrease the surface tension of electrospray 127 
droplets[2], and therefore altering concentrations could affect the supercharging process, 128 
which relies on increases in surface tensions by m-NBA [2].   129 
 130 
Figure S7  The effect of formic acid content on glucagon SRM peaks area using m-NBA 131 
based mobile phases. Mobile phases are A= ACN, B= H2O/ACN (95/5), both modified with either (a) 132 
0.05% m-NBA with at 0, 0.010, 0.025, 0.050, or 0.0100% FA, or (b) 0.01% m-NBA with at 0, 0.010, 133 
0.025, 0.0100, or 0.500% FA. Values are means of n≥3 replicate injections of 1000 pg/mL surrogate 134 
matrix standards. 135 
5.2 Effect of m-NBA modified mobile phases upon analysis of GLP-1 and Glucagon 136 
Solutions and Plasma Extracts  137 
A SRM method was created with 13 transitions (8 GLP-1 transitions and 5 for Glucagon or 138 
Glucagon IS) (Figure S8 and Figure S9). The SRM transitions encompassed the 5+ and 6+ 139 
parent ions for glucagon, and the 3, 4, 5 and 6+ parent ions for GLP-1. Product ions were 140 
identified by fragmentation of these parent ions, followed by collision energy optimisation. 141 
Multiple transitions were monitored to increase the likelihood of finding those with low 142 
background noise (thereby increasing signal to noise) along with the absence of 143 
interferences. A greater number of GLP-1 transitions were selected, as glucagon SRM 144 
transitions had been previously investigated. 145 
A 20ms dwell time was used to ensure sufficient data points across the peaks. Scheduled 146 
MRM was used to maximise dwell time by only monitoring glucagon and GLP-1 transitions 147 
near their RT (1.6 and 2.5 respectively), a target scan time of 0.2 seconds, and MRM 148 
detection window of 30 seconds was selected.  149 
Surrogate matrix and extracted plasma samples spiked to the 1200 pg/mL level with 150 
glucagon and GLP-1 were analysed using mobile phase modified with 0.05% or  151 
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0.01% m-NBA. These percentages were found to give the most intense analyte signal when 152 
glucagon solutions were analysed (Section 5.1.1). The mobile phases also contained either 153 
0.01% FA, found to be optimal for glucagon solution analysis (Section 5.1.2) or 0.1% FA. 154 
The higher acid concentration was evaluated to investigate whether this was needed for 155 
effective analyte ionisation due to competition from matrix components. 156 
The effect of altering mobile phases was similar for surrogate matrix (solution) samples and 157 
plasma extracts for both glucagon (Figure S8) and GLP-1 (Figure S9). In most cases it was 158 
noted that plasma extracts gave a lower signal, although this will at least in part be due to 159 
the loss of compound during the extraction, rather than difference in ionisation between the 160 
matrices. Mobile phases containing  0.05% and m-NBA 0.01% FA were found to give 161 
maximum signal, regardless of transition, nature of sample (plasma or solution), and analyte. 162 
The presence of matrix therefore did not alter the supercharging process. It was noted that 163 
some transitions were affected by the alteration in mobile phases more than others; 164 
demonstrating that supercharging of the analyte alters the intensity of various product ions 165 
formed. 166 
 167 
Figure S8  Glucagon peak areas for 1200 pg/mL solution and plasma extracts under 168 
different mobile phase conditions.  1200 pg/mL solution or plasma extracts were analysed, values 169 
are means of n=3 replicates. 170 
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Figure S9  GLP-1 peak areas for 1200 pg/mL solution and plasma extracts under different 172 
mobile phase conditions.  1200 pg/mL solution or plasma extracts were analysed, values are 173 
means of n=3 replicates.  174 
5.3 Comparisons of the optimised m-NBA modified mobile phase with the original 175 
formic acid mobile phase method 176 
A plasma sample was spiked with 1200 pg/mL glucagon and GLP-1, and analysed with 177 
optimal m-NBA based mobile phase method (modified with 0.05% m-NBA 0.01% FA) and 178 
the original formic acid based method (modified with 0.2% FA). The signal-to-noise was 179 
assessed for each transition monitored (Table 4). 180 
The transitions highlighted were selected for further assessments using either standard 181 
mobile phases (blue) or supercharging mobile phase (red). Although these were not always 182 
the transitions that gave the best S/N, they gave best overall performance when linearity and 183 
precision and accuracy were considered.  184 
The SRM method was subsequently altered to remove redundant transitions, and split into 185 
separate methods for method for analysis with formic acid and supercharging mobile phase 186 
methods to maximise dwell time for each transitions to improve sensitivity.  In addition 187 
scheduled MRM was replaced with periods, as this was found to improve signal. 188 
 189 
Table 4  Signal-to-noise in various SRMs obtained by analysis of a 1200 pg/mL 190 
glucagon and GLP1 plasma extract, analysed using m-NBA or the original formic acid modified 191 
mobile phases.  192 
Glucagon 
transition 
S/N GLP-1 
transition 
S/N 
0.2% FA 0.05% MNBA 
0.01% FA 
0.2% FA  0.05% MNBA 
0.01% FA 
581.1/575.3 N/A 31.1 550.5/547.5 N/A 18.0 
581.1/578.2 N/A 26.9 550.5/601.5 N/A 14.5 
697.5/639.8 17.6 15.4 550.5/639.3  N/A 10.8 
   660.1/656.7  12.0 3.4 
   660.1/751.5 7.0 8.1 
   825.1/458.2 N/A N/A 
   825.1/946.4 4.1 N/A 
   1099.5/1093.7 N/A N/A 
Mobile phases are A= ACN and B=water (or water/ACN 95/5 for m-NBA modification), modified as 193 
shown in the table. N/A- not applicable, as no peak was observed 194 
  195 
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5.4 Comparison of SIL internal standard response of a surrogate matrix and 196 
extracted plasma sample    197 
  198 
Figure S10  SIL gluagon internal standard response in a) a non-extracted surrogate matrix 199 
sample, and b) an extracted plasma sample 200 
a) b) 
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6 Establishment Procedures (Supplemental Tables)  201 
 202 
Table 5 Precision and accuracy of surrogate matrix and extracted plasma glucagon samples 203 
analysed using LC-MS/MS with either the original formic acid modified mobile phases, or  204 
m-NBA modified mobile phases 205 
Sample ID Surrogate/ 
Plasma 
Nominal 
concentration 
(pg/mL) 
0.2% FA Phases 
Glucagon 
(697.5/694.0) 
0.05%  m-NBA 
0.01% FA phases 
Glucagon 
(581.5/578.5) 
%RE %CV %RE %CV 
QC LLOQ Surrogate 15 110.3 11.9 96.9 15.4 
QC LOW Surrogate 45 113.8 6.2 110.9 11.8 
(QC LLOQ)* Plasma 25 
1
 92.6 7.0 90.6 10.0 
(QC LOW)* Plasma 75 
1
 92.4 11.3 99.6 10.9 
QC MED Plasma 200 
1
 91.4 8.7 100.0 9.7 
QC MED (Lith Hep) Plasma 200 
2
 92.6 9.0 119.0 9.3 
QC MED (inter matrix) Plasma 200 
3
 106.3 4.5 111.7 5.3 
QC Dilution Plasma  1750 
4
 84.9 6.7 78.1 8.3 
QC HIGH Plasma 1750 
1
 98.0 10.7 106.1 12.2 
Green statistics are within 20% RE or <20% CV for glucagon, or within 25% RE or <25 % CV for 206 
GLP-1 207 
*  = QC level created for GLP-1 analysis, but additionally monitored for glucagon to improve assay 208 
characterisation 209 
1 = 31.9 pg/mL / 37.5 pg/mL endogenous glucagon measured using formic acid / m-NBA phases, and 210 
added to the spiked concentration  211 
2 = No endogenous glucagon detected in lithium heparin plasma used 212 
 3= Adjusted for endogenous glucagon concentration determined in each individual matrix 213 
4= No endogenous glucagon detected in matrix used for dilution QCs 214 
 215 
  216 
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Table 6  Glucagon matrix effects determined using LC-MS/MS with either the original 217 
formic acid modified mobile phases, or m-NBA modified mobile phases 218 
Matrix 
ID 
0.2% FA Phases 
Glucagon (697.5/694.0) 
0.05%  m-NBA 
 0.01% FA phases 
Glucagon (581.5/578.5) 
Analyte 
ME 
IS 
ME 
ME 
Ratio 
Analyte 
ME 
IS 
ME 
ME 
Ratio 
F1 1.58 1.48 1.07 1.09 0.985 1.10 
F2 1.36 1.43 0.951 1.01 1.05 0.961 
F4 1.33 1.34 0.992 0.924 0.899 
 
 
1.03 
F5 1.30 1.47 0.882 1.16 1.19 0.979 
M1 1.33 1.21 1.10 0.922 0.792 1.16 
M4 1.32 1.20 1.09 0.656 0.591 1.11 
Mean 1.37 1.36 1.01 0.960 0.918 1.06 
SD 0.104 0.127 0.0881 0.176 0.209 0.0806 
%CV 7.615 9.34 8.7 18.354 22.82 7.62 
ME (Matrix Effect) = Adjusted Peak Area (Plasma)/ Peak Area (surrogate matrix) 219 
Adjusted Area= Peak area of plasma ME sample- Peak area of endogenous plasma sample 220 
ME ratio= Analyte ME/ IS ME 221 
 Green statistics have ME Ratios within 20% of 1, or %CV20% 222 
.223 
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Table 7 Precision and accuracy of extracted plasma GLP-1 samples analysed using LC-MS/MS with formic acid (top) or m-NBA (bottom) modified 224 
mobile phases with either the analogue or SIL glucagon internal standard. Green statistics are within 25% RE or <25%CV. Red statistics are outside 225 
these criteria.  NA –not analysed, as 660.1/751.5 was determined to be optimal before these experiments were conducted.  226 
Sample ID Surrogate/ 
Plasma 
Nominal 
concentration 
(pg/mL) 
0.2% FA Phases 
GLP-1 (660.1/656.7) 
0.2% FA Phases 
GLP-1 (660.1/751.5) 
No IS Heavy 
Glucagon 
Des-7-Thr-
Glucagon 
No IS Heavy 
Glucagon 
Des-7-Thr-
Glucagon 
%RE %CV %RE %CV %RE %CV %RE %CV %RE %CV %RE %CV 
QC LLOQ Plasma 25 102.2 18.2 88.0 11.6 86.9 16.7 131.4 20.1 118.6 20.0 112.7 24.6 
QC LOW Plasma 75 102.6 13.1 113.1 13.6 113.8 11.7 103.7 22.4 110.2 11.3 107.4 13.6 
QC MED Plasma 200 107.9 16.6 107.4 7.7 109.6 8.4 108.6 10.7 107.3 2.0 107.2 6.7 
QC MED (Lith Hep) Plasma 200 NA NA NA NA NA NA 72.9 15.6 81.9 12.6 75.2 12.9 
QC MED (inter matrix) Plasma 200 NA NA NA NA NA NA 149.1 15.4 134.5 16.0 122.9 16.3 
QC DIL Plasma 10,000 73.1 9.6 72.1 10.5 74.7 11.8 76.6 6.7 75.7 8.8 76.8 10.0 
QC HIGH Plasma 1750 99.7 15.6 111.6 2.7 113.9 5.8 102.9 15.5 113.8 3.6 113.8 6.7 
 227 
Sample ID Surrogate/ 
Plasma 
Nominal 
concentration 
(pg/mL) 
0.05% m-NBA 0.01% FA phases 
(550.5/601.5) 
0.05%  m-NBA 0.01% FA phases 
(550.5/693.3) 
No IS Heavy 
Glucagon 
Des-7-Thr-
Glucagon 
No IS Heavy 
Glucagon 
Des-7-Thr-
Glucagon 
 %RE %CV %RE %CV %RE %CV %RE %CV %RE %CV %RE %CV 
QC LLOQ Plasma 25 88.0 25.6 75.1 36.6 75.1 33.8 75.0 43.2 57.5 39.8 63.4 33.0 
QC LOW Plasma 75 83.9 17.3 107.0 19.6 103.9 15.8 71.0 15.5 104.4 25.3 96.0 22.8 
QC MED Plasma 200 80.2 14.1 94.8 8.8 94.4 7.2 75.0 13.6 91.4 11.5 88.3 12.8 
QC MED (Lith Hep) Plasma 200 NA NA NA NA 59.9 19.4 NA NA NA NA NA NA 
QC MED (inter matrix) Plasma 200 NA NA NA NA 177.1 37.5 NA NA NA NA NA NA 
QC DIL Plasma 10,000 63.8 12.4 75.8 7.4 74.6 8.3 63.6 13.7 83.1 7.2 76.6 7.9 
QC HIGH Plasma 1750 80.1 12.8 99.6 16.8 107.4 12.2 78.7 13.6 103.2 18.4 106.8 14.1 
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Table 8  GLP-1 matrix effects determined using LC-MS/MS with the original formic acid 228 
modified mobile phase and the analogue glucagon internal standard.  See footnotes on 229 
Table 6. 230 
Matrix ID 0.2% FA Phases 
GLP-1 (660.1/751.5) with analogue glucagon IS 
Analyte ME IS ME Ratio 
F1 1.14 1.41 0.808 
F2 0.869 1.33 0.653 
F4 0.876 1.40 0.628 
F5 0.735 1.34 0.548 
M1 1.02 1.24 0.827 
M4 0.765 1.19 0.641 
Mean 0.901 1.32 0.684 
SD 0.154 0.0860 0.110 
%CV 17.1 6.5 16.1 
 231 
 232 
Table 9  Inter-batch reproducibility of endogenous glucagon determination.  233 
Replicate Measured Endogenous Glucagon Concentration (pg/mL) 
Initial Analysis Reanalysis after 42 Days  
storage at -80C 
1 29.7 34.0 
2 31.1 36.5 
3 33.8 31.7 
4 32.7 35.7 
5 34.2 33.8 
6 29.9 27.9 
Mean 31.9 33.3 
SD 1.95 3.11 
CV 6.1 9.4 
% Difference  4.3 
Formic acid modified mobile phases used.  234 
% Difference=100* ((Reanalysis concentration –Initial concentration) / Initial concentration) 235 
  236 
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Table 10  Performance of QCs in stabilised plasma vs non-stabilised plasma. 237 
Anticoagulant Stabiliser Freeze-thaw 
cycles 
% Non-stabilised  
QC concentration 
Glucagon GLP-1 
EDTA None 0 113.3 77.9 
EDTA  0 94.8 99.7 
EDTA D 0 102.9 104.9 
EDTA AD 0 109.1 107.0 
EDTA AD 1 101.1 86.2 
EDTA AD 2 109.5 95.0 
Lithium Heparin None 0 81.7 84.1 
Lithium Heparin A 0 98.1 97.1 
Lithium Heparin D 0 91.1 105.9 
Lithium Heparin AD 0 98.0 113.7 
Formic acid modified mobile phases used 238 
200 pg/mL of glucagon/GLP-1 was spiked into a variety of matrices, as shown, and compared to 239 
the performance of QCs spike in non-stabilised EDTA plasma. 240 
Green statistics are within 20/25% (Glucagon/GLP) of non-stabilised QC response. 241 
 242 
Table 11  Ability to reinject sample extracts after 42 days storage at 4C 243 
Surrogate/ 
Plasma Matrix 
Nominal 
Concentration  
(pg/mL) 
Glucagon GLP-1 
 %RE %CV %RE %CV 
Surrogate 15 107.1 11.6 N/A N/A 
Surrogate 25 106.0 11.3 N/A N/A 
Surrogate 45 111.3 7.8 N/A N/A 
Plasma 25# 86.5 7.6 116.6 7.4 
Plasma 75# 87.7 10.1 99.3 24.8 
Plasma 200# 89.6 10.0 98.4 7.3 
Plasma 1750# 99.0 13.6 104.7 22.2 
Formic acid modified mobile phases used.  244 
#31.4 pg/mL endogenous concentration added to glucagon QC concentration 245 
Green statistics are within 20% RE or <20%CV (Glucagon) or 25% RE or <25%CV (GLP-1).246 
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7 Cross validation against established immunoassays using physiological samples 247 
 248 
 249 
Figure S11 Comparison of endogenous glucagon concentrations determined by LC-MS/MS, Milliplex and HTRF immunoassays. 250 
Samples were analysed from 5 volunteers (1-5), which contained either EDTA (E) or Lithium Heparin (L) anticoagulant in addition to various stabilisers (not 251 
shown). Different stabiliser combinations were used in samples of the same Sample Type, e.g. the four 4E samples in Figure 11a are all unique. a) All 252 
concentrations determined. b) Concentrations above the LLOQ only shown (≥10.0/ 13.0 / 12.0 pg/mL for LC-MS/MS / Milliplex / HTRF respectively).253 
0
10
20
30
40
50
60
70
1E 1E 1E 1E 1L 1L 1L 1L 1E 1E 2E 2E 2E 2E 2L 2L 2L 2L 2E 2E 3E 3E 3E 3E 3L 3L 3L 3L 3E 3E 4E 4E 4E 4E 4L 4L 4L 4L 4E 4E 5E 5E 5E 5E 5L 5L 5L 5L 5E 5E
 G
Lu
ca
go
n
 C
o
n
ce
tr
at
io
n
 (
p
g/
m
L)
 
Sample Type 
All concentrations HTRF
Milliplex
LC-MS/MS
0
10
20
30
40
50
60
70
1 E 1 E 1 E 1 L 1 L 1 L 1 L 1 E 1 E 2 E 2 E 2 E 2 E 2 L 3 E 3 E 3 E 3 E 3 L 3 L 3 L 3 L 4 E 4 E 4 E 4 E 4 L 4 L 4 L 4 L 4 E 4 E 5 E 5 E 5 E 5 L 5 L 5 L 5 L 5 E
G
lu
ca
go
n
 C
o
n
ce
n
tr
at
io
n
 (
p
g/
m
L)
 
Sample Type 
Concentrations ≥ LLOQ 
HTRF
Milliplex
LC-MS/MS
a) 
b) 
19 
 
8 References  254 
[1]  Howard JW, Kay RG, Tan T, et al. Development of a high throughput UHPLC-MS/MS (SRM) 255 
method for the quantitation of endogenous glucagon from human plasma. Bioanalysis. 6(24), 256 
3295–3309 (2014). 257 
[2]  Iavarone AT, Williams ER. Mechanism of charging and supercharging molecules in 258 
electrospray ionization. J. Am. Chem. Soc. 125(8), 2319–27 (2003). 259 
 260 
